Robert Tansley

Robert Tansley is Cambridge Innovation Capital (CIC) plc’s Investor Director for Microbiotica and is also an Investment Director with Cambridge Innovation Capital (CIC), focussed on healthcare and associated technologies; a post he has held since 2014.

After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA, and Roche. Before joining CIC Robert spent 10 years in senior management roles in a number of start-up companies, including Arakis and KalVista; he founded the malaria-focused company Treague and was founding CEO of the University of Copenhagen spin-out Avilex Pharma.

Robert qualified in medicine from University College London. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine, and has an MBA from London Business School and an MPhil in Biostatistics from the University of Cambridge.